CP
ARCT icon

Castleview Partners’s Arcturus Therapeutics ARCT Stock Holding History

Castleview Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,857
Closed -$130K – 227
2026
Q1 		$130K Buy
+16,857
New +$123K 0.07% 190

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Castleview Partners's ARCT Position: Q2 2026 in Review

Castleview Partners sold out of Arcturus Therapeutics (ARCT) in Q2 2026, closing a stake of 16,857 shares — an estimated $130K sold.

Castleview Partners first reported a position in ARCT in Q1 2026 and held it in 1 quarter. The position peaked at $130K in Q1 2026. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Castleview Partners reported no remaining Arcturus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Castleview Partners sold 16,857 Arcturus Therapeutics shares in Q2 2026, an estimated $130K.
  • Castleview Partners first reported a position in Arcturus Therapeutics in Q1 2026 and held it in 1 quarter.
  • Castleview Partners's Arcturus Therapeutics position peaked at $130K in Q1 2026.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Castleview Partners's 13F filing for Q2 2026, filed 20 Jul 2026.